Evidence map›Paper›PMID 34860164›Full record

ArticleBalkan medical journal2021

Clinical Characteristics and Mutation Spectrum of Neurofibromatosis Type 1 in 27 Turkish Families.

Shahrashoub Sharifi, Tuğba Kalaycı, Şükrü Palanduz, Şükrü Öztürk, Kıvanç Cefle

Open access · diamondAbstract read
In one paragraph

Article in Balkan medical journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Shahrashoub SharifiDivision of Medical Genetics, Department of Internal Medicine, İstanbul School of Medicine, İstanbul University, İstanbul, Turkey.
Tuğba KalaycıDivision of Medical Genetics, Department of Internal Medicine, İstanbul School of Medicine, İstanbul University, İstanbul, Turkey.
Şükrü PalanduzDivision of Medical Genetics, Department of Internal Medicine, İstanbul School of Medicine, İstanbul University, İstanbul, Turkey.
Şükrü ÖztürkDivision of Medical Genetics, Department of Internal Medicine, İstanbul School of Medicine, İstanbul University, İstanbul, Turkey.
Kıvanç CefleDivision of Medical Genetics, Department of Internal Medicine, İstanbul School of Medicine, İstanbul University, İstanbul, Turkey.
Istanbul University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNeurofibromatosis type 1 (NF1) is a neurocutaneous disorder that results in a predisposition to the growth of multiple tumors in the central nervous system, the peripheral nervous system, and the skin. The clinical manifestations of neurofibromatosis are associated with loss of neurofibromin expression which causes the upregulation of the RAS pathway. Although neurofibromatosis type 1 can be diagnosed based on the National Institutes of Health criteria, sometimes the diagnosis is difficult, in cases where the characteristic features do not develop. Moreover, other RAS-related disorders may present with significantly overlapping clinical features.

aimsTo determine the clinical and molecular genetic characteristics of Turkish patients with neurofibromatosis type 1. STUDY

designCross-sectional study.

methodsFor the genetic analysis of 27 Turkish families clinically diagnosed with NF1 between 1990 and 2019, we used a multi-step process consisting of next-generation sequencing, multiplex ligation-dependent probe amplification, and array-comparative genomic hybridization.

resultsIn this study, we identified 11 novel and 11 previously reported single-nucleotide variants in 22 families. Whole gene deletions were detected by multiplex ligation-dependent probe amplification analysis in 3 families. Of those, array comparative genomic hybridization analysis defined a 17q11.2 deletion in 4 patients from 2 families and 1.2-Mb involving 1 unrelated patient. All patients with a deletion had facial dysmorphism, suggesting a peculiar phenotype in this group. We could not find any pathogenic variant in the 2 families that met the National Institutes of Health criteria.

conclusionThe novel pathogenic variants identified in this study broaden the spectrum of pathogenic variants in NF1 and provide better clinical characterization of NF1. RNA-seq experiments are recommended in patients who meet the National Institutes of Health diagnostic criteria for NF but have not identified any variants in nextgeneration sequencing, multiplex ligation-dependent probe amplification, or array-comparative genomic hybridization analysis.

Indexed as

Comparative Genomic HybridizationCross-Sectional StudiesGene DeletionGenetic Predisposition to DiseaseHumansMutationNeurofibromatosis 1Neurofibromin 1TurkeyNeurofibromin 1

Identifiers

PMID34860164
PMCPMC8880985
OpenAlexW3205094819

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.